Avecure Flexible Microwave Ablation Probe For Lung Nodules

Not Applicable

Recruiting

• Conditions: Stage I - II Primary Lung Cancer; Stage II Lung Cancer; Lung Cancer Stage I; Lung Cancer Stage II; Stage I Lung Cancer; Lung Cancer
• Interventions: Device: AveCure 16 Gauge Flexible Microwave Ablation Probe

• Registration Number: NCT05281237
• Lead Sponsor: Beth Israel Deaconess Medical Center

Brief Summary

This research study to determine the effectiveness of the AveCure Flexible Microwave Ablation Probe to destroy cancerous lung nodules up to 3 c m in size.

This research study involves microwave ablation (MWA)

Detailed Description

This will be a single arm, prospective cohort study.

The names of the study intervention involved in this study is:

* Cone Beam Computed Tomography (CBCT)-guided electromagnetic navigational bronchoscopy (ENB) microwave ablation (MWA)

* A rapid on-site evaluation (ROSE) will be performed before the MWA to confirm that the lesion is malignant, this can lead to longer procedure time and time under anesthesia.

The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.

* Participants will receive the study intervention and will be followed for 30 days.

* It is expected that about 10 people will take part in this research study.

This research study is a Pilot Study, which is the first-time investigators are examining this intervention using a bronchoscopic approach for microwave ablation of solitary pulmonary nodules.

The U.S. Food and Drug Administration (FDA) has approved this intervention as a treatment option for this disease.

Study Timeline

• Study First Submitted: 2022-02-16
• Study First Submitted QC: 2022-03-11
• Study First Posted: 2022-03-16
• Study Start: 2022-06-01
• Status Verified: 2025-02
• Last Update Submitted: 2025-02-03
• Last Update Posted: 2025-02-05
• Primary Completion: 2026-12-30
• Study Completion: 2027-06-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

• Subject with Stage I - II primary lung cancer (Solitary nodules up to 3 cm) as defined by previous pathology or ROSE.
• Pathological proof of target nodule/tumor type and malignancy with specimen considered adequate per institutional laboratory standards
• Target nodule/tumor which can be accessed via navigational bronchoscopy and confirmed location with cone beam CT scan intra-operatively
• Resection/surgical candidate (lobectomy or greater)
• Participants must be at least 22 years old and able to provide consent

Exclusion Criteria

• Subjects in whom flexible bronchoscopy is contraindicated
• Target nodule < 1.0 cm
• Prior radiation or neo adjuvant chemotherapy of the target nodule/tumor
• Any comorbidity that the investigator feels would interfere with the safety of the subject or the evaluation of study objectives
• Pacemaker, implantable cardioverter, or another electronic implantable device
• Patient cannot tolerate bronchoscopy
• Patients with coagulopathy
• Patients in other therapeutic lung cancer studies
• Subject is pregnant or breastfeeding
• COVID-19 positive patient at the time of procedure.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
AVECURE FLEXIBLE MICROWAVE ABLATION PROBE FOR LUNG NODULES	AveCure 16 Gauge Flexible Microwave Ablation Probe	The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits. * Ablation Procedure- MWA will be used to treat solitary pulmonary nodules up to 3cm. * CT scan will then be performed to evaluate the radiological changes 2 - 4 weeks after the ablation procedure. * Surgery will be performed to remove the lung nodule and the tissue will be evaluated by pathology.

Primary Outcome Measures

Name	Time	Method
Rate of Planned Ablations.	Day 1	Feasibility of performing the procedure as planned in the enrolled patients. At least 9/10 of the planned ablations (90%) can be performed bronchoscopically according to the established protocol.
Pathological changes in the tumor tissue.	4 weeks	Pathological evaluation of the acute thermal effect produced by the AveCUre 16G-FMAP on targeted malignant solitary lung nodules will be described. The % necrosis, % viable tumor, and % stroma/inflammation present in the targeted nodules after ablation will be described.

Secondary Outcome Measures

Name	Time	Method
Histological changes in lung tissue outside the zone of predicted ablation.	4 weeks	A secondary analysis of the tissue surrounding the treated area will be performed. The % necrosis and of % stroma/inflammation will be described.
Immune-histochemical changes in the tumor tissue.	4 weeks	Immune-histochemical evaluation including TTF-1, Napsin-A, p40, or other immune-histochemical assessments will be performed if needed on a per case basis.

Trial Locations

Locations (1)

Beth Israel Deaconess Medical Center; 🇺🇸 Boston, Massachusetts, United States